Regeneron Pharmaceuticals Earnings: Here’s Why Shares are Up Now

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 3.97%.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Regeneron Pharmaceuticals, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased 1518.18% to $1.78 in the quarter versus EPS of $0.11 in the year-earlier quarter.

Revenue: Rose 89.68% to $439.66 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Regeneron Pharmaceuticals, Inc. reported adjusted EPS income of $1.78 per share. By that measure, the company beat the mean analyst estimate of $0.95. It beat the average revenue estimate of $424.26 million.

Quoting Management: “The first quarter of 2013 was a productive quarter where we delivered sustained revenue and earnings growth,” said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. “EYLEA sales in the U.S. continue to enjoy strong growth and we are raising our estimate of full year U.S. EYLEA net sales to $1.25 to $1.325 billion in 2013. The ex-U.S. launch of EYLEA by our partner, Bayer HealthCare, is also going very well and resulted in a positive contribution to our earnings this quarter. Our broad, late-stage pipeline is making progress. We expect our first data from the alirocumab Phase 3 program for reducing LDL cholesterol in the second half of 2013. We reported positive data with our IL-4R inhibitor, dupilumab, in atopic dermatitis and additional data for dupilumab are expected in allergic asthma later this month.”

Key Stats (on next page)…

Revenue increased 6.04% from $414.6 million in the previous quarter. EPS increased 45.9% from $1.22 in the previous quarter.

Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $1.31 to a profit $1.05. For the current year, the average estimate has moved down from a profit of $5.12 to a profit of $4.4 over the last ninety days.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]